And Scientists Just Discovered It May Be Behind Cancer, MS and Autoimmune Disease
Epstein-Barr Virus — Symptoms, Causes, Long-Term Risks & the 2026 mRNA Vaccine Breakthrough
The Virus Inside Almost Everyone — And Why It Matters
There is a virus inside about 90% of all adults that live on earth today. It’s a pretty safe bet that you have it. Probably you didn’t know you had it when you were young. It did not produce symptoms, your immune system fought off the infection and you lived your normal life.
However, the virus never went away. It’s alive and present, but hidden in your body in a latent form. But researchers are finding that this dormancy isn’t as benign as we thought.
It is known as Epstein-Barr virus (EBV). It was found in 1964 and was the first virus to be proved as a cause of cancer in humans. It was chiefly known for its ability to produce glandular fever, the run-down disease associated with adolescence, which everyone refers to as the kissing disease. Unpleasant, but temporary. Get it, get well, move on.
The situation in 2026 is a lot more complicated. The 20-year study of 10 million soldiers found a 32-fold risk of MS following EBV infection. It has been linked to other autoimmune disorders such as lupus, rheumatoid arthritis, inflammatory bowel disease and celiac disease. A Group 1 carcinogen and responsible for more than 200,000 new cases of cancer each year worldwide.
This guide covers everything: What is EBV, how it spreads, what are symptoms of it, why it is life-long, its relationship to serious disease, the recent 2026 research that has found out, and the mRNA vaccine, now in clinical trials, that could change everything.
2026 Breakthrough — FDA Approves mRNA Vaccine Trial for EBV-Related Cancer
In March 2026, the FDA approved an Investigational New Drug application for WGc-043 — an mRNA therapeutic vaccine for Epstein-Barr virus-related cancers — showing superior safety and efficacy in trials for nasopharyngeal cancer and NK-cell lymphoma. Separately, University of Basel researchers published results in Science (February 2026) identifying a metabolic pathway that can suppress latent EBV infection and reduce downstream disease risk.
Table of Contents
What Is Epstein-Barr Virus?
Epstein-Barr virus is part of a group of viruses called the herpesviruses, which is the same family of viruses that causes cold sores (HSV-1), chickenpox (varicella-zoster) and cytomegalovirus. One thing that is common to all herpesviruses is that they are lifelong residents. Can be controlled, but not eradicated.
EBV targets only two cell types: those of the immune system (B cells make antibodies) and the epithelial cells (lining the throat and mucous membranes). It exists in 3 forms: Primary infection (it is active and can cause symptoms), Latency (it is dormant in B cells), Periodic lytic reactivation (it is active again for a short period when the immune system becomes suppressed and/or under stress).
It is the latency phase that is now at the centre of scientific attention. EBV encodes a few proteins which are called EBV nuclear antigens (EBNAs) and latent membrane proteins (LMPs) during latency that facilitate its undetectability. The same proteins are now known to be involved in the growth of cancer and to stimulate the immune system of vulnerable individuals.
How EBV Spreads — The Kissing Disease and Beyond
EBV is spread mainly through saliva – thus the kissing disease nickname of glandular fever. However, it’s much more contagious than casual kissing implies. The known ways that the infection spreads include sharing cups, water bottles, or cutlery, coughing and sneezing at close range, and rarely, blood transfusion or organ transplant.
Most children are infected by close contact with each other physically in the early years, which is common in developing countries. Usually an infection at this age is asymptomatic, meaning that the infection is cleared up by the immune system without any symptoms occurring, and no one will ever know.
Many children in higher-income countries do not get the virus early in childhood, but get it for the first time later in adolescence or early adulthood. At this time, the immune response is stronger—this is what gives rise to the dramatic symptoms of infectious mononucleosis. It is NOT the virus that overcomes the body! It is not the immune system’s battle that is the disease, but the intense battle of the immune system itself.
Infective period is 4–6 weeks after exposure to symptoms.
EBV Symptoms — From No Symptoms to Weeks of Illness
In Young Children
Most children don’t have any symptoms associated with an EBV infection. The immune system takes care of the virus, but without producing any noticeable sickness. That’s why most adults have EBV and have no recollection of ever being infected.
In Teenagers and Young Adults — Infectious Mononucleosis (Glandular Fever)
If the EBV infection happens during adolescence/early adulthood, the disease is much more severe. Infectious mononucleosis — also called mono or glandular fever — is characterised by:
- Severe difficult tiredness — different from normal tiredness; hard to get rid of even after a long sleep and can last for several months
- Very sore throat, usually accompanied by white patches or pus on the tonsils; often incorrectly diagnosed as bacterial tonsillitis or strep throat
- High temperature (usually 38-40 centigrade)
- Swollen lymph glands (lymph nodes), especially in the neck area, as well as in the armpits and groin areas
- Swollen spleen (splenomegaly): up to 50% of these may risk rupture with impact
- Swollen liver and mild hepatitis — liver enzymes are elevated in nearly all cases and some cases may be jaundiced
- Headache, muscle tenderness and deep general weakness
- Characteristic skin rash — usually an EBV drug reaction, and not a penicillin allergy; especially when using amoxicillin or ampicillin antibiotics;
The acute phase usually lasts 2-4 weeks. Fatigue may last for months; sometimes there is a post-infectious fatigue syndrome in some individuals that lasts for six months or more.
EMERGENCY — Seek Immediate Medical Help If
Sudden severe abdominal pain develops — this could indicate splenic rupture, a life-threatening emergency. | Extreme difficulty breathing or swallowing — possible airway obstruction from severely swollen tonsils. | Confusion or seizures appear. | Avoid ALL contact sports and heavy lifting for at least 4 to 6 weeks. Splenic rupture during this window can be fatal. Call 999 (UK) or 911 (US) immediately for any of these symptoms.
Why EBV Never Leaves — The Lifelong Latency Problem
Once the acute disease is over, EBV hides out in a small subset of long-lived B lymphocytes, and becomes latent for life. The virus does not replicate in this state and only makes a few proteins, it replicates silently with normal cell division and is largely hidden from the immune system.
Now, a study by the Wistar Institute published in Nucleic Acids Research in July 2025 has uncovered, for the first time, just how EBV protein EBNA-LP takes advantage of this spot. It essentially changes the shape of DNA in infected B cells, making it accessible to parts of the genome that cannot be reached, and thereby initiating pathways to cancerous cell growth. The scientists termed it the virus hijacking the host genome and turning on genes that should not be turned on.
This is how EBV can lead to serious disease in a significant minority of individuals when it is dormant in most of the population for most of the time. The trigger seems to be the combination of a viral strain, host genetic susceptibility and immune status. Life can be dire when the scales are out of balance.
EBV-Associated Diseases — The Full Picture
The spectrum of diseases now associated with Epstein-Barr virus is much broader than most — and many clinicians — realize:
| Category | Disease | EBV Connection |
| Cancer | Burkitt lymphoma | First cancer proven to be caused by EBV; most common childhood cancer in sub-Saharan Africa |
| Cancer | Hodgkin’s lymphoma | EBV present in up to 40% of classical Hodgkin’s cases |
| Cancer | Nasopharyngeal carcinoma | Almost universally EBV-associated; predominant in Southeast Asia |
| Cancer | Gastric (stomach) cancer | Approximately 10% of all stomach cancers are EBV-driven |
| Cancer | NK/T-cell lymphoma | Rare aggressive lymphoma; EBV consistently identified |
| Cancer | Post-transplant lymphoma | Driven by reactivated EBV in immunosuppressed transplant recipients |
| Autoimmune | Multiple sclerosis | 32-fold increased MS risk after EBV infection (10-million person military cohort) |
| Autoimmune | Systemic lupus (SLE) | EBV infection rates elevated 50-fold in children who develop lupus |
| Autoimmune | Rheumatoid arthritis | EBV consistently found in joint tissue and blood of RA patients |
| Autoimmune | Inflammatory bowel disease | Linked to both Crohn’s disease and ulcerative colitis |
| Autoimmune | Celiac disease | EBV-driven immune disruption may trigger gluten sensitivity |
| Autoimmune | Sjögren’s syndrome | Salivary glands are a primary site of EBV infection and transmission |
EBV and Multiple Sclerosis — The Most Important Discovery
Epitopes from EBV are involved in auto-immune disease via a mechanism known as molecular mimicry. EBV proteins are similar in structure to proteins in the body, especially in the protective sheath of nerve fibres in the brain and spinal cord (myelin). The immune system can make antibodies against EBV that cross-react with myelin, which can cause the autoimmune response leading to MS.
The nub of the 2022 US military study was the evidence. After tracking 10 million soldiers over 20 years, the researchers concluded that nearly all cases of MS were EBV infections that occurred earlier in life — and that a recent EBV infection was linked with a 32-fold higher risk of MS. This is one of the strongest casual links found between pathogen and auto-immune disease.
EBV infection rates are increased up to 50-fold in children who develop lupus. EBNA2 binds to thousands of sites in the human genome, including many of the same sites that are associated with susceptibility to other autoimmune disorders such as lupus, MS and rheumatoid arthritis.
The Vaccine Implication
If a preventive EBV vaccine blocks initial infection, it may also prevent multiple sclerosis in vaccinated populations — one of the most compelling public health arguments in medicine today. This logic is now driving major research investment into EBV vaccine development worldwide.
Diagnosis and Treatment
How EBV Is Diagnosed
- Monospot test (heterophile antibody test) — quick test performed at the bedside; positive in 85% of adult cases of mono, but less reliable in children or early illness
- Blood film — the characteristic blood abnormality seen with mono is atypical lymphocytes
- EBV serology: VCA-IgM – acute infection; VCA-IgG – past infection; EBNA antibodies appear weeks/month after infection.
- The blood chemistry tests performed on liver function tests — increased enzymes in nearly all mono cases.
- EBV PCR (viral load) — detects active viral replication; indicated for immunocompromised patients and suspected EBV associated cancers.
How EBV Is Treated
No antiviral drugs are available for EBV nor is there a vaccine approved. The treatment of acute infectious mononucleosis is purely supportive:
- Rest — the most important intervention; forcing through fatigue is a sure way to make illness last longer.
- Analgesic (pain relief) — paracetamol or ibuprofen for muscle pain, sore throat and fever
- Proper fluid intake (particularly if there is any pain involved with swallowing)
- Do not engage in contact sports or heavy lifting for 4-6 weeks — enlarged spleen can be at risk of rupture
- Do not consume alcohol — the liver is making a huge effort to deal with it.
- Antibiotics (penicillin) — if infection is causing tonsils to become enlarged and swollen.
- Do NOT take amoxicillin or ampicillin— these give a rash in 90% of mono patients and are often reported as a penicillin allergy.
The 2026 EBV Vaccine — Genuine Hope on the Horizon
Since 2022, Moderna has been conducting Phase I clinical trials of two mRNA EBV vaccine candidates. mRNA-1189 is designed to prevent initial EBV infection — encoding five viral glycoproteins that block both the B cell and epithelial cell entry mechanisms. mRNA-1195 is for treating people who are already sick with the disease but want to prevent more serious complications.
In March 2026, the FDA approved an Investigational New Drug (IND) application for WGc-043, an mRNA therapeutic vaccine targeting cancers associated with the Epstein-Barr virus (EBV) which demonstrated superior safety and efficacy in completed investigator-initiated trials compared to other currently available mRNA cancer vaccines. In addition, the University of Basel in February 2026 published findings of a metabolic pathway that can inhibit latent EBV infection, decreasing the likelihood of downstream disease — a parallel line of therapy that complements vaccine development.
A preventative EBV vaccine could have an impact in modern medicine that has few parallels — over 200,000 people could be spared from cancer every year, and vaccinated populations could see their MS cases cut in half and their rates of lupus, rheumatoid arthritis and inflammatory bowel disease drop significantly. The quest to neutralise this virus is picking up pace.
Frequently Asked Questions
Q: What is Epstein-Barr virus?
Epstein-Barr virus (EBV) is part of the herpesvirus family and is very common: it infects around 90% of adults worldwide. It is the main source of the infectious mononucleosis (glandular fever) and the first virus discovered to cause cancer in humans. EBV stays latent in B cells after the initial infection, and is associated with more than 200,000 cancer cases each year, as well as multiple sclerosis, lupus, rheumatoid arthritis, and other autoimmune diseases.
Q: Does everyone with EBV get glandular fever?
No. The vast majority of people who get infected with EBV when they are young are asymptomatic. IM is most commonly seen in teens and young adults during the first time they have an EBV infection, when the immune system is more robust and therefore a more serious illness. Following the acute phase, the virus goes into lifelong latency, no matter how mild or severe the initial infection is.
Q: Can EBV cause cancer?
Yes. EBV is a Group 1 carcinogen (the highest cancer risk classification), and directly associated with six types of cancer: Burkitt’s lymphoma, Hodgkin’s, nasopharyngeal, a subset of gastric, NK/T-cell, and post-transplant lymphoproliferative disorder. EBV-related cancers worldwide are responsible for more than 200,000 new cases and some 150,000 deaths annually.
Q: Is there a vaccine for EBV in 2026?
There is no approved EBV vaccine available and clinical development is well underway. Moderna’s mRNA EBV vaccines (mRNA-1189 and mRNA-1195) have been undergoing Phase I trials since 2022. The FDA granted approval for clinical trials with WGc-043, an mRNA therapeutic vaccine with promising results against EBV-associated cancers, in March 2026. The efficacy of a preventive EBV vaccine may have the additional benefit of reducing the incidence and burden of autoimmune disease in addition to its cancer prevention properties.
Q: Why is EBV linked to multiple sclerosis?
A 2022 study of 10 million military personnel in the USA revealed an association with EBV infection and a 32-fold greater risk for MS: almost all MS cases had prior EBV infection. The most common mechanism is the molecular mimicry in which proteins on the EBV virus resemble proteins that coat nerve fibres (myelin), so that immunity against EBV causes antibodies to attack the myelin. This is the most compelling evidence of a single environmental factor that ever has been found for MS.
Conclusion — The Virus We All Carry and What It Means
EBV is not just the virus that gives you a bad few weeks in your teens. It is a permanent presence in the body that has been proven to be associated with cancer, multiple sclerosis, lupus, rheumatoid arthritis, inflammatory bowel disease and celiac disease – all affecting hundreds of millions of people around the world.
Two breakthroughs emerged from the 2025 and 2026 research: a mechanistic understanding of how EBV rewires the DNA to promote cancer as well as the strongest evidence so far that it’s possible to inhibit latent EBV infection with targeted metabolic and vaccine strategies.
Tell someone who suffered from glandular fever and didn’t know about the research’s findings on the lasting impacts of the disease. If you or your relatives have an autoimmune disease, especially MS or lupus, consult your doctor if you have any EBV-related concerns.
Medical Disclaimer
This article is for informational purposes only. Always consult a qualified healthcare professional for personal medical advice.